Merck Sharp & Dohme LLC v. Mylan Pharmaceuticals Inc. et al.

I'll research this case thoroughly before drafting the overview.

Now let me verify the judge, appeal outcome, and IPR proceedings.

Let me verify the judge, procedural path (MDL), and the appeal outcome.

I'll research this case thoroughly across PACER, PTAB, and legal news sources.

Let me dig into the docket timeline, the IPR decisions, and the appeal/settlement details.

I'll research the press coverage across multiple angles.

Press & analysis coverage

The September 2022 trial win was covered as a franchise-level exclusivity story rather than a damages story. The verdict itself reached the press via Merck's own announcement: BioSpace carried Merck's September 22, 2022 release stating that the N.D. W. Va. court "found that both Merck patents at issue were valid and infringed," identifying U.S. Patent No. 7,326,708 (the sitagliptin dihydrogen phosphate salt, expiring Nov. 24, 2026, with pediatric exclusivity to May 24, 2027) and U.S. Patent No. 8,414,921 (the sitagliptin/metformin co-formulation, expiring Jan. 21, 2029, with pediatric exclusivity to July 21, 2029). FiercePharma framed it as Merck having "successfully parried a Viatris patent assault," noted that Viatris "opted against a patent settlement and instead took its arguments to trial" while Merck had "inked at least 21 settlements with generics companies allowing them to launch in May 2026 or earlier 'under certain circumstances,'" and put 2021 Januvia/Janumet sales at roughly $5.3 billion. PharmaLive ran the same substance on September 23, 2022, and Drug Store News and World Pharmaceutical Frontiers repeated the release largely verbatim, including the detail that "Judge Irene Keeley presided over the trial" and that "Merck was represented by the law firm of Williams & Connolly." Merck's trial team itself publicized the result in a Williams & Connolly case note, which dates the ruling to September 22, 2022, describes a December 2021 bench trial, and says the win "followed a settlement on the eve of trial of related matters that had been coordinated as an MDL proceeding in the District of Delaware." Notably, no outlet reported a damages figure or royalty — consistent with a § 271(e)(2) ANDA case where the relief is an approval-date remedy; the "number" in the coverage is market size, not money judgment.

The Federal Circuit's affirmance of the PTAB got its own, legally richer round of coverage. IPWatchdog (Eileen McDermott, Sept. 29, 2022) reported that the court, in a precedential opinion by Judge Lourie, upheld the Board's finding that Mylan failed to show claims 1–4, 17, 19, and 21–23 of the '708 patent anticipated or obvious over Edmondson (WO 2003/004498 / U.S. 6,699,871), Brittain, and Bastin, quoting the court's reasoning that "a class of 957 predicted salts that may result from the 33 disclosed compounds and eight preferred acids… is insufficient to meet the 'at once envisage' standard." Law-firm analysis tracked the same holding with more doctrinal detail: Finnegan published a note titled "957 Salts — Too Many to 'At Once Envisage,'" and K&L Gates' Adriana Burgy and Thomas Irving wrote a two-part National Law Review series on Merck's pre-AIA § 102(e)/§ 103(c) common-ownership strategy and its inherent-anticipation defense at the Board. These pieces treat the case as significant for the narrow reading of In re Petering ("the key term here is 'limited'") — a point the general pharmaceutical press almost entirely missed.

Reporting diverges from the record in several identifiable ways. First, timing: the trade press reported the district court ruling on September 21–22, 2022, whereas the public memorandum opinion in this docket is Doc. 204, filed October 26, 2022 — consistent with a sealed ruling later unsealed/refiled, but worth flagging because it means contemporaneous coverage predates the public opinion and could not have been checked against it. Citeline went further and dated the district court decision September 29 — the same day as the Federal Circuit ruling — which conflates the two. Second, characterization: pharmaphorum and Citeline described the Federal Circuit as having "upheld the validity" of the patent; technically the court affirmed the Board's non-unpatentability determinations in Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp., No. 21-2121 (Fed. Cir. Sept. 29, 2022) — a PTAB affirmance, not a validity judgment. Third, party framing: pharmaphorum described the West Virginia case as "a district court case brought by Viatris," inverting the parties (Merck was plaintiff); GxP News and Pharmvestnik repeated the same Reuters-derived account in Russian, and both credit Reuters for the underlying reporting — I was unable to retrieve the Reuters article itself, so the Reuters URL is not cited here. Fourth, one coverage strand goes well beyond the litigation: Citeline's Medicare-pricing piece uses the win to illustrate the tension created by Januvia's selection for IRA drug-price negotiation, an editorial/analyst frame with no counterpart in the docket.

The settlement and its terms received thinner, secondary coverage. Salud y Fármacos summarized an Endpoints News report (Paul Schloesser, March 20, 2023) that the parties had asked Judge Keeley to enter final judgment in 1:19-cv-00101-IMK following remand, under a proposal barring Mylan affiliates from making, using, or selling any ANDA product in the U.S. until after both the '708 and '921 patents expire, with approval contingent on the Federal Circuit's issuance of the mandate. I could not retrieve the original Endpoints article, so that account is cited only as summarized. Two caveats on the article list supplied with this task: I located the IPWatchdog "Patent Filings Roundup" piece by Jonathan Stroud (Feb. 11, 2022), but the retrieved text addresses the Rosen Technologies/IPVal smart-thermostat filings and filing statistics and discloses no case-specific passage on Merck v. Mylan — so I cannot attribute any statement about this case to it.

Two discrepancies with the case metadata. (1) Coverage and Doc. 204 both show that U.S. Patent No. 8,414,921 was also at issue in the trial (Merck asserted '921 claim 1 alongside '708 claim 3, and the court found infringement of both), while the metadata lists only the '708. (2) The metadata's "judgment; on appeal" status should be read as to the '708 PTAB track: the Federal Circuit appeal of the PTAB decision was resolved against Mylan on September 29, 2022, while the district court judgment was resolved by the March 2023 settlement/consent-judgment request rather than by a merits appellate decision. I found no press report of any Federal Circuit merits ruling on Judge Keeley's infringement holding.

Sources

• CAFC Affirms Merck’s Win at PTAB over Mylan Challenge to Diabetes Treatment Claims - CAFC Affirms Merck’s Win at PTAB over Mylan Challenge to Diabetes Treatment Claims
• United States Court of Appeals for the Federal Circuit
• FINNEGAN
• Litigation Archives - Posts in Litigation
• 首先，PTAB認定於Edmondson組合中未明確揭露1：1西他列汀DHP鹽之所有限制，且Mylan學名藥廠無法證明該發明所屬技術領域中具通常知識者能藉由Edmondson組合而「立刻思及（at once envisage）」該些限制
• Moreover, even assuming a 1:1 sitagliptin DHP salt was identified in WO '498, Merck provides evidence, for example, that anhydro...
• UNITED STATES PATENT AND TRADEMARK OFFICE
• Published on The National Law Review https://dev
• Mylan Archives - Posts Tagged: "Mylan"
• IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
• IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
• UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

I'll research the docket and firm sources to identify plaintiff's counsel of record.

Good initial hits. Now let me verify the local counsel history, the appellate team, and individual attorney details.

I'll research the docket and firm sources for defense counsel in this case.

Let me dig into the specific defense attorneys and their firms.

Counsel of Record for the Defendant(s)

Threshold party note

Counsel must be read against the current party structure. Mylan Inc. was dismissed from this action by stipulation early on; only Mylan Pharmaceuticals Inc. ("MPI") remained a defendant at trial. The court confirmed this in its post-trial opinion: "Although Merck originally included Mylan Inc. as a defendant in this action, the parties previously stipulated to its dismissal" (Doc. 204 at 1 n.1, Oct. 26, 2022). Pre-dismissal filings (e.g., the June 2021 withdrawal motion) were captioned "Mylan Inc., Mylan Pharmaceuticals Inc.", but the live defense team is MPI's team. Note also that this action was part of MDL No. 2902 (In re: Sitagliptin Phosphate ('708) Patent Litigation), transferred to the District of Delaware before Judge Andrews and remanded to Judge Keeley in August 2021 — so the same team also appeared in Delaware during the MDL phase.

Defense attorneys